Zacks Investment Research upgraded shares of Arvinas (NASDAQ:ARVN) from a sell rating to a hold rating in a research report released on Wednesday morning.

According to Zacks, “Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States. “

Other analysts also recently issued research reports about the company. Piper Jaffray Companies began coverage on Arvinas in a research report on Monday, October 22nd. They issued an overweight rating and a $23.00 price objective for the company. Goldman Sachs Group started coverage on Arvinas in a research report on Monday, October 22nd. They issued a neutral rating and a $17.00 price objective for the company. Finally, Citigroup started coverage on Arvinas in a research report on Monday, October 22nd. They set a buy rating and a $21.00 target price for the company.

Shares of ARVN stock traded up $0.20 during mid-day trading on Wednesday, reaching $16.47. The stock had a trading volume of 46,984 shares, compared to its average volume of 57,463. Arvinas has a one year low of $10.19 and a one year high of $21.25.

Several institutional investors have recently bought and sold shares of the stock. Gilder Gagnon Howe & Co. LLC bought a new position in shares of Arvinas during the 3rd quarter worth approximately $129,000. Citadel Advisors LLC bought a new position in shares of Arvinas during the 3rd quarter worth approximately $463,000. Birchview Capital LP bought a new position in shares of Arvinas during the 3rd quarter worth approximately $506,000. Dean Capital Investments Management LLC bought a new position in shares of Arvinas during the 3rd quarter worth approximately $631,000. Finally, EcoR1 Capital LLC bought a new position in shares of Arvinas during the 3rd quarter worth approximately $844,000. Institutional investors and hedge funds own 41.89% of the company’s stock.

About Arvinas

Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer.

Featured Article: Catch-Up Contributions

Get a free copy of the Zacks research report on Arvinas (ARVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.